FIELD: biotechnology.
SUBSTANCE: group of inventions including a bispecific agent that binds claudin 6 (CLDN6) and CD3, a recombinant nucleic acid, a host cell for the expression of a bispecific agent, the use of a bispecific agent, a recombinant nucleic acid or a host cell for the manufacture of a pharmaceutical composition for the treatment or prevention of cancer, characterized by cancer cells expressing CLDN6, a pharmaceutical composition for treating or preventing cancer characterized by cancer cells expressing CLDN6 and a method for treating or preventing a cancer characterized by cancer cells expressing CLDN6 are described.
EFFECT: invention expands the arsenal of agents binding to claudin 6 (CLDN6) and CD3.
21 cl, 54 dwg, 12 tbl, 34 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS AND COMPOSITIONS FOR PREDICTION OF THERAPEUTIC EFFICIENCY OF TREATMENT OF ONCOLOGICAL DISEASES AND PREDICTION OF ONCOLOGICAL DISEASES | 2016 |
|
RU2785291C2 |
| COMBINATION THERAPY USING ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER TREATMENT | 2014 |
|
RU2792932C2 |
| BISPECIFIC TRIVALENT ANTIBODIES BINDING TO CLAUDIN 6 OR CLAUDIN 18.2 AND CD3 FOR THE TREATMENT OF ONCOLOGICAL DISEASES WITH CLAUDIN EXPRESSION | 2017 |
|
RU2798988C2 |
| MULTIVALENT Fv-ANTIBODIES | 2016 |
|
RU2785766C2 |
| C10orf54 ANTIBODIES AND USE THEREOF | 2015 |
|
RU2714232C2 |
| ANTI-C10orf54 ANTIBODIES AND APPLICATIONS THEREOF | 2015 |
|
RU2819627C1 |
| INDUCIABLE BINDING PROTEINS AND THEIR USE | 2017 |
|
RU2800034C2 |
| ANTI-CLAUDIN ANTIBODIES AND USE THEREOF | 2019 |
|
RU2815926C2 |
| ANTIBODY AGAINST CLAUDIN 18A2 AND ITS USE | 2020 |
|
RU2811431C2 |
| ANTIBODY SPECIFICALLY BINDING TO N-TERMINAL REGION OF LYSYL-TRNA-SYNTHETASE EXPOSED ON CELL MEMBRANE | 2018 |
|
RU2739393C1 |
